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Abstract
Mucosal tolerance to E-selectin prevents stroke and protects against ischemic brain damage in experimental models of
stroke studying healthy animals or spontaneously hypertensive stroke-prone rats. A reduction in inflammation and neural
damage was associated with immunomodulatory or ‘‘tolerogenic’’ responses to E-selectin. The purpose of the current study
on ApoE deficient mice is to assess the capacity of this stroke prevention innovation to influence atherosclerosis, a major
underlying cause for ischemic strokes; human E-selectin is being translated as a potential clinical prevention strategy for
secondary stroke. Female ApoE2/2 mice received intranasal delivery of E-selectin prior to (pre-tolerization) or
simultaneously with initiation of a high-fat diet. After 7 weeks on the high-fat diet, lipid lesions in the aorta, serum
triglycerides, and total cholesterol were assessed as markers of atherosclerosis development. We also assessed E-selectin-
specific antibodies and cytokine responses, in addition to inflammatory responses that included macrophage infiltration of
the aorta and altered gene expression profiles of aortic mRNA. Intranasal delivery of E-selectin prior to initiation of high-fat
chow decreased atherosclerosis, serum total cholesterol, and expression of the leucocyte chemoattractant CCL21 that is
typically upregulated in atherosclerotic lesions of ApoE2/2 mice. This response was associated with the induction of E-
selectin specific cells producing the immunomodulatory cytokine IL-10 and immunosuppressive antibody isotypes.
Intranasal administration of E-selectin generates E-selectin specific immune responses that are immunosuppressive in
nature and can ameliorate atherosclerosis, a major risk factor for ischemic stroke. These results provide additional preclinical
support for the potential of induction of mucosal tolerance to E-selectin to prevent stroke.
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Introduction
Atherosclerosis is a major cause and contributor to stroke. With
15 million strokes each year that result in death or permanent
disability in 2/3 of cases, stroke is the second leading cause of
death and the leading cause of long-term disability worldwide [1].
This burden will increase greatly during the next two decades due
to population aging [2]. Despite decades of intensive research,
therapeutic options for acute stroke are still very limited and only a
small proportion of patients can benefit from recombinant tissue
plasminogen activator, aspirin, or hemispheric decompression [2].
In this regard, alleviating factors contributing to stroke as a
preventative measure is critical for lowering stroke-associated
mortality or disability. Additionally, it cannot be ignored that
other organs (e.g. heart, kidney) and multiple vascular beds are
also affected by atherosclerosis [3,4].
From atherosclerotic plaque development within arterial walls to
end-stage thrombotic complications, inflammatory processes play key
roles in all stages of atherosclerosis [4,5]. Limiting immune cell
activation and recruitment has been shown to attenuate atheroscle-
rosis and its complications [6,7]. In several diseases with inflamma-
tory or autoimmune components, T cells with immunosuppressive
qualities, including T regulatory cells (Tregs), are indispensable for
maintaining immune homeostasis and unresponsiveness to self-
antigen [8]. Mechanisms of Treg suppression vary depending on the
type of cell, but can involve cell-contact dependent or independent
pathways, suppressor cytokines (TGF-b,IL-10,etc.),andimmunecell
killing [9]. In the model of mucosal tolerance [10], it has been shown
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associated lymphoid tissues preferentially prime T helper lympho-
cytes that produce either IL-10 or TGF-ß upon subsequent antigen
exposure. In this regard, oral or intranasal delivery of a variety of
antigens to induce Tregs and associated immunomodulation has
been used successfully in treating atherosclerosis, autoimmune
diseases, transplant rejection, and allergy in several animal models
[11,12,13,14,15,16].
E-selectin is a cell surface glycoprotein adhesion molecule that is
induced exclusively on activated endothelium and mediates the
adhesion of leukocytes [17]. Cleavage of its extracellular domain
leads to the detection of soluble E-selectin in serum, increased
levels of which have been observed in subarachnoid hemorrhage
[18], atherosclerosis [19], multiple sclerosis [20], end stage renal
disease [21], and acute strokes [22]. Our group has found that
intranasal delivery of E-selectin prevents spontaneous ischemic
and hemorrhagic strokes [23] and protects against ischemic brain
damage [24]. Intranasal delivery of E-selectin has been shown to
influence many inflammatory and neuroprotective aspects of
cerebrovascular disease, including the ability to increase the
number of Treg/Foxp3+ cells in the ischemic brains [25], reduce
vessel activation [26] and infiltration of CD8+ cells [24], and
enhance survival of neural progenitor cells and neurons [25].
These studies employed animal models of stroke including animals
with hypertension as well as healthy animals undergoing
surgically-managed brain ischemia by middle cerebral artery
occlusion and demonstrated the specificity to E-selectin versus
irrelevant antigens such as ovalbumin (OVA) [23]. The effect of E-
selectin tolerization on atherosclerosis, the underlying disease for
the majority of strokes, has not been investigated.
In this study, we sought to investigate the role of intranasal
delivery of E-selectin in modulating inflammatory events and
lesion development in a mouse model of atherosclerosis in order to
assess the capacity of this stroke prevention innovation to favorably
affect this recognized stroke risk factor.
Materials and Methods
Ethics Statement
The study was approved by the National Institute of
Neurological Disorders and Stroke Animal Care and Use
Committee (Protocol #1260-06).
Delayed type hypersensitivity (DTH) reaction
For delayed type hypersensitivity (DTH) studies, female
C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) main-
tained on regular mouse chow underwent tolerization with either
5 mg OVA (Calbiochem, La Jolla, CA) or 5 mg human E-selectin
(Novavax, Rockville, MD) at 9 weeks of age. Intranasal delivery
was carried out with the animals under brief anesthesia with 1.5%
isoflurane. Ten ml OVA or E-selectin (0.5 mg/ml) was delivered
into one nostril every other day for 9 days (total of 5
administrations), defined as a single-round tolerization. Two
weeks after the last intranasal delivery, animals were sensitized
with 55 mg E-selectin in 0.5 mg/ml complete Freund’s adjuvant
(Difco Laboratories, Detroit, MI). Thirteen days later, animals
were divided into two groups and challenged in the right and
left ears with 10 ml PBS or PBS containing 5 mg E-selectin
respectively. Ear swelling was measured as a relative change in ear
thickness using microcalipers at 48 hrs.
Animals and diet in atherosclerosis model
Female ApoE2/2 mice on a C57BL/6 background (Jackson
Laboratory, Bar Harbor, ME) were assigned randomly to two
treatment groups receiving either human E-selectin or PBS
intranasally (Biowhittaker, Walkersville, MD). Ten ml PBS or E-
selectin (0.5 mg/ml) was delivered in one round of tolerization; 2
weeks later, mice received another round of tolerization. The
animals were fed regular mouse chow before the start of a high-fat
diet, Cocoa Butter Diet and Purina Mouse Chow (Harlan Teklad,
Madison, WI). Animals were observed daily and weighed weekly.
Animals in this pilot study were assessed after 7 weeks on high-
fat diet and having received either regimen A (N=10 per group),
with intranasal administration begun at the start of high-fat diet; or
regimen B (pre-tolerization, N=25 per group), with intranasal
administrations completed just prior to the initiation of high-fat
diet (Figure 1). In regimen A, after 7 weeks on high-fat diet, we
collected aortas (for En Face), and splenocytes (for T cell
proliferation and cytokine assays); after 13 weeks on high-fat diet,
we collected upper hearts and proximal aortas for immunohisto-
chemistry from 5 mice per group. In regimen B, after 7 weeks on a
high-fat diet, we collected aortas (10 mice per group for En Face
and 5 mice per group for Movet staining), and splenocytes (5 mice
per group for T cell proliferation and cytokine assays); after 10
weeks on a high-fat diet, we collected aortic RNA and performed
microarray (3 mice for PBS group, 4 mice for E-selectin group).
For both regimens, we collected serum for all analyses performed
on serum after 7 weeks on a high-fat diet (5 mice per group in
regimen A and 24 mice for the PBS group and 23 mice for the E-
selectin group in regimen B).
Aortic lipid lesion quantitation and histopathology
Animals were fasted for four hours before blood draw and
serum collection with Z-gel from Sarstedt (Newton, NC) according
to manufacturer’s instructions and stored at –80uC. After 7 weeks
on high-fat diet, splenocytes were collected for cell culture and
mice were perfused with 10 ml 0.9% NaCl and 10 ml perfusion
solution (10% formalin, 5% sucrose, 5.8 g/L EDTA). For En Face
analysis, the aorta and heart were carefully removed and stained
(0.5% Sudan IV, 35% ethanol and 50% acetone) for 30 min,
followed by 80% ethanol 30 min, water 1 h, and stored in
perfusion solution. Extraneous fatty tissue and connective tissue
were carefully trimmed away and the aorta cut longitudinally and
mounted on a slide. Plaque lesions in the region extending from
aortic root to 6 mm distal (including ascending aorta and arch)
were quantitated using a microscopic CCD-IRIS camera and
MetaMorph software (Molecular Devices, Downingtown, PA).
Sections of aortic root from mice on regimen B were collected at
necropsy, placed in perfusion solution, routinely processed and
sectioned, and stained with Movat and Alcian blue-PAS-
hematoxylin for histopathological evaluation in a blinded fashion.
Immunohistochemistry
The upper heart and proximal aorta were embedded in Tissue-
Tek OCT (Sakura Finetek USA, Torrance, CA) and sectioned
serially at 10 mm thickness. Beginning with the first section
containing all three valves, a section was stained every 80 mm. Five
mice per treatment group and five sections per mouse were used
for immunohistochemistry. Sections were fixed in cold acetone for
10 min, followed by 0.5% hydrogen peroxide 10 min, 1% BSA +
10% rabbit serum 2 h, MOMA-2 antibody (ABD Serotec,
Raleigh, NC) at 1 mg/ml overnight, HRP conjugated rabbit
anti-rat Fcc (Jackson ImmunoResearch, West Grove, PA) at
0.4 mg/ml 1 h. Color was developed with DAB (Vector Lab,
Burlingame, CA) and nuclei counterstained with Hematoxylin QS
(Vector Lab). Rat IgG was used as a control. Macrophage positive
area per cross-section and fractional macrophage positive area
(macrophage positive area divided by the area inside external
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(Molecular Devices, Downingtown, PA).
Serum total cholesterol and triglyceride measurement
Serum total cholesterol and triglyceride levels were measured
using Stanbio Cholesterol LiquiColor and Stanbio Triglyceride
LiquiColor kits (Stanbio Lab, Boerne, TX) according to
manufacturer’s recommended protocols. For triglyceride mea-
surement, serum was used directly; for total cholesterol, serum was
diluted to 1/8 with 0.9% NaCl. The concentrations of the total
cholesterol and triglyceride were calculated from a standard curve.
Antibody assays
Plates were coated overnight with 50 ml 5 ng/ml mouse E-
selectin (R&D Systems, Minneapolis, MN) in PBS, blocked with
5% BSA in PBS 1 h, incubated with 1/200 diluted mouse serum
2 h. Biotin conjugated goat anti-mouse IgG, IgG1, IgG2a and
streptavidin-HRP were from Jackson ImmunoResearch. Following
1 h incubation with secondary antibody, streptavidin-HRP diluted
1/1000 was added to each well and incubated for 20 min. Color
was developed with TMB (3, 39,5 ,5 9 tetramethyl benzidine,
Sigma, St. Louis, MO) and stopped with 2N H2SO4. The
absorbance was read at 450 nm. Fifty ml 5 ng/ml OVA coated
plates were used to monitor non-specific antibody binding (with
serum from OVA immunized C57BL/6 mice used as a positive
control).
T cell proliferation and cytokine assays
Splenocytes (4610
5) were incubated in X-vivo 15 serum free
media (Lonza, Walkersville, MD) with or without 20 mg/ml E-
selectin or 20 mg/ml OVA. After collecting tissue culture
supernatants at 72 h, 1 mCi of [
3H]-thymidine (PerkinElmer,
Waltham, MA) was added to each well for an additional 16 h, cells
were harvested on a TomTec IIIM cell harvester (Hamden, CT)
and incorporated radioactivity was measured on a Wallac
Microbeta Trilux (PerkinElmer, Waltham, MA). Cytokine analysis
was performed by sandwich ELISA using IL-2, IL-4, IL-10, TGF-
b, IL-17, IFNc, and TNFa mouse DuoSet kits (R&D Systems) per
manufacturer’s directions. Serum soluble mouse E-selectin,
ICAM-1, VCAM-1 and TGF-b were measured with kits from
R&D. Duplicate samples were assayed.
RNA purification, microarray, and real-time RT-PCR
After ten weeks on a high-fat diet, 3 animals receiving PBS and
4 animals receiving E-selectin on regimen B (pre-tolerization) were
used in the microarray analysis. After perfusion with PBS, the
aorta was carefully removed, snap frozen in liquid nitrogen, and
ground with a pestle and mortar on dry ice. RNA was purified by
AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, CA).
RNA quality and quantity was ensured using the Bioanalyzer
(Agilent, Santa Clara, CA) and NanoDrop (Thermo Scientific,
West Palm Beach, FL) respectively. Per RNA labeling, 200 ng of
total RNA was used in conjunction with the Affymetrix
recommended protocol for the Affymetrix Mouse Genome ST
1.0 GeneChip (Santa Clara, CA).
‘‘RMA Sketch’’ (Expression Console, Affymetrix) was used to
summarize probe measurements and generate normalized gene
fragment expression values for each hybridized cRNA. Quality of
data was assured via sample-level inspection by Tukey box plot,
covariance-based PCA scatter plot, and correlation-based Heat
Map. Gene fragments not having at least one expression value
greater than system noise were deemed ‘‘non-informative’’ and
discarded. System noise was defined as the lowest expression value
at which the LOWESS fit of observed CV for each gene fragment
by mean expression value for each gene fragment changes from
non-linear to linear. For gene fragments not discarded, expression
Figure 1. Treatment regimens. Mice received 2 rounds of intranasal delivery of E-selectin or PBS. The 2 rounds of intranasal delivery were
separated by 2 weeks and each round of intranasal delivery was composed of 5 doses (PBS or 5 mg E-selectin per dose) with 1 dose (10 ml) every other
day. In regimen A (N=10 per group), we initiated the intranasal delivery of solutions and the high-fat diet simultaneously. In regimen B (N=25 per
group), we gave the mice intranasal delivery of solutions prior to initiating the high-fat diet.
doi:10.1371/journal.pone.0020620.g001
E-Selectin Tolerization in ApoE2/2 Mice
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20620values were floored to equal system noise if less than system noise
and subject to the Welch Modified t-test for association with
tolerization. Expression values for gene fragments providing an
uncorrected P-value , 0.05 and an absolute fold difference of
means $1.25 were deemed associated with tolerization. Annota-
tion information for genes deemed associated with tolerization
were obtained via IPA (Ingenuity, Redwood City, CA).
Abundance of CCL21 mRNA was determined using Quanti-
Tect SYBR Green RT-PCR Kit (Qiagen, Valencia, CA). The
primer sequences were obtained from PrimerBank (Harvard
University, Cambridge, MA) with a slight modification of the
CCL21 forward primer to detect both A and B variants of CCL21;
CCL21 forward primer: CATCCCGGCAATCCTGTTCT;
ccl21 reverse primer: GGGGCTTTGTTTCCCTGGG; GAPDH
forward primer: AGGTCGGTGTGAACGGATTTG; GAPDH
reverse primer: TGTAGACCATGTAGTTGAGGTCA. Ten ng
total RNA was reverse transcribed for 30 minutes at 50uC.
Following 15 min at 95uC, the cDNA was amplified by 40 cycles
of: 94uC 15 seconds, 62uC 30 seconds, and 72uC 30 seconds. The
CCL21 expression was normalized to the expression of GAPDH
and the results were expressed as fold changes in mRNA
expression with respect to the control animals.
Statistical analysis
Data are expressed as mean 6 standard error of the mean
(SEM). Mann Whitney Rank Sum Test was used in comparing the
T cell proliferation, cytokines in cell culture supernatant, and
serum antibodies between the two treatment groups. Other data
passed normality tests and were analyzed by two-tailed student’s t-
test. Differences were considered significant at P,0.05.
Results
Delayed type hypersensitivity
Previous work from our laboratory demonstrated E-selectin
tolerization significantly limits Th1 mediated DTH reactions
mounted in rats following sensitization and challenge with human
E-selectin [23,27,28]. Comparisons to both PBS and OVA-
tolerized animals highlighted the specificity of the response to E-
selectin. After testing a range (0.1 to 10 mg) of tolerizing doses with
a similar regimen in a C57BL/6 mouse model of multiple sclerosis,
experimental autoimmune encephalomyelitis (EAE; Jacqueline A.
Quandt, unpublished data, 2010), the 5 mg dose was found to be
most effective at limiting clinical disease and was selected for the
current study. In C57BL/6 mice, 5 mg of E-selectin given
intranasally significantly reduced ear swelling, a response which
was highly specific to E-selectin (Figure 2) with negligible
reductions in OVA-tolerized mice. Intranasal E-selectin reduced
swelling by more than 50% compared to OVA tolerized animals
(P=0.007) with no significant differences observed in PBS-
sensitized ears. Delivery of E-selectin alone to the ear pad did
not elicit swelling beyond that measured for PBS in animals naive
to E-selectin (data not shown).
Analysis of ApoE2/2 animals tolerized with E-selectin
Not knowing whether E-selectin tolerization would have an
effect once high-fat diet and associated atherosclerosis develop-
ment were already underway, we tested the influence of E-selectin
tolerization either simultaneously with initiation of a high-fat diet
(regimen A) or pre-tolerization with completion prior to start of
high-fat diet (regimen B). Two-rounds of intranasal delivery of
5 mg E-selectin previously afforded optimal protection in rat stroke
models [24,25] and was similarly applied in each of these regimens
(Figure 1). Within each regimen, we analyzed factors associated
with atherosclerosis development and additional immune proper-
ties in animals after high-fat diet consumption for 7 weeks. Daily
body weight and food intake were similar between the two
treatment groups, and veterinary staff monitoring animals daily
noted no atypical behaviors, physical conditions nor increased
incidence of lesions or infections (morbidity or mortality) in E-
selectin treated animals compared to controls. Regardless of
regimen, animals in the two treatment groups had similar body
weight over the course of the study (Table 1).
Increased serum cholesterol is a major risk factor for the
development of atherosclerosis in humans and genetically
engineered mice. ApoE2/2 mice show increased levels of serum
total cholesterol and triglycerides compared to wild-type litter-
mates that are further increased when animals receive a high-fat
diet [29] and develop severe atherosclerosis. In regimen A (5 mice
per group), no statistical difference in serum total cholesterol was
detected between the 2 groups (Table 1) receiving PBS or E-
selectin simultaneously with the introduction of high-fat diet.
Animals receiving E-selectin prior to starting a high fat-diet
showed modestly reduced serum total cholesterol levels (P=0.003)
compared to PBS controls, yet serum triglyceride levels were not
statistically different.
Intranasal delivery of E-selectin reduces atherosclerosis
We assessed atherosclerosis in En Face sections after 7 weeks on
a high-fat diet. Consistent with other studies in mouse models of
atherosclerosis, the majority of the lipid lesions were located near
the aortic root and arch. In regimen B, 52.062.7% of the surface
area of the ascending aorta and arch were covered with
atherosclerotic lesions in PBS group, yet pre-tolerization with E-
selectin caused a significant 26.4% plaque reduction (38.264.5%
of the ascending aorta and arch, P=0.02) (Figure 3A and B).
Regimen A was less effective at reducing the atherosclerosis on the
ascending aorta and arch (40.4610.0% in PBS group versus
24.668.8% in E-selectin group, P=0.27).
Where early E-selectin administration showed reduced lipid
deposition, the sections of aortic roots (5 mice per group in
regimen B) were stained with Movat staining (Figure 3C) and
Figure 2. Intranasal delivery of E-selectin reduces swelling in a
delayed type hypersensitivity reaction. 9 week old mice under-
went one round (consisting of five intranasal administrations every
other day) of 10 ml PBS containing either 5 mg OVA (white bars) or E-
selectin (black bars). After sensitization and subsequent challenge with
E-selectin, responses to E-selectin were significantly reduced in animals
previously receiving E-selectin versus those receiving OVA intranasally
(P=0.007). Swelling was not significantly different in the ears
challenged only with PBS between the two treatment groups. N=5
mice per group, error bars represent SEM.
doi:10.1371/journal.pone.0020620.g002
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and basement membrane thickening or disruption. Endothelial
damage was minimal in all tissues studied. Animals in both groups
showed similar mild or mild to moderate reticulin fiber
degeneration. Basement membranes in both groups were equally
disrupted and showed similar degrees of subintimal thickening and
fibrosis.
Although no difference was observed in atherosclerosis after 7
weeks in regimen A, a subset of animals receiving simultaneous E-
selectin at the start of a high-fat diet were followed for an
additional 6 weeks and processed to allow examination histolog-
ically. After 13-weeks on a high-fat diet, macrophage infiltration in
the aortic roots of mice on regimen A was quantitated by
immunohistochemistry. Mice receiving E-selectin showed a trend
toward reduced macrophage infiltration compared with mice
receiving PBS (4.460.6610
5 mm
2 in PBS group versus
3.260.3610
5 mm
2 in E-selectin group, P=0.11). The percentage
of lumen area positive for macrophages gave similar results
(27.661.9% in PBS group versus 23.361.4% in E-selectin group,
P=0.11). Notably, fewer than 10 CD3
+ or Foxp3+ cells were
observed per section with no significant difference between the
PBS or E-selectin treatment groups.
Intranasal delivery of E-selectin induces E-selectin specific
immune cells
Spontaneous or background proliferation of cultured spleno-
cytes was similar for both of the PBS and E-selectin treatment
Table 1. Analysis of serum lipids and cell adhesion molecules.
PBS E-selectin
Characteristics Mean ± SEM N Mean ± SEM N P
Regimen A
Body weight, g 16.8 6 0.5 5 16.7 6 0.4 5 0.930
Triglycerides, mg/dL NA NA
Total cholesterol,
mg/dL
2024.3 6 139.1 5 1912.9 6 131.4 5 0.577
sE-selectin, ng/ml 432.1657.8 5 425.5647.1 5 0.931
sICAM-1, ng/ml 35.862.6 5 33.861.2 5 0.520
sVCAM-1, ng/ml 1955.2675.7 5 2100.0669.8 5 0.198
Regimen B
Body weight, g 19.1 6 0.3 25 19.0 6 0.4 24 0.777








sE-selectin, ng/ml 581.8619.5 15 595.7634.3 14 0.730
sICAM-1, ng/ml 38.761.7 21 35.261.5 22 0.122
sVCAM-1, ng/ml 2577.2641.9 21 2443.2671.5 22 0.115
Sera were collected from animals in either regimen after 7 weeks after on a
high-fat diet. N indicates the number of mice.
doi:10.1371/journal.pone.0020620.t001
Figure 3. Intranasal delivery of E-selectin reduces atherosclerosis. Mice treated with regimen A (N=5 per group) or regimen B (N=10 per
group) were processed En Face after 7 weeks on a high-fat diet. The lipid lesions in the aorta were stained with Sudan IV. (A) Representative photos
illustrate the predominance of lesions in the aortic arch. (B) Quantification of lipid lesion on the ascending aorta and arch. In regimen B, pre-
tolerization with E-selectin caused a significant 26.4% plaque reduction in the surface area of the ascending aorta and arch. (C) Movat staining of
cross-sections of the aortic root in regimen B. The PBS and E-selectin groups showed similar degrees of pathology in the aortic roots.
doi:10.1371/journal.pone.0020620.g003
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observed only in animals that received E-selectin intranasally;
proliferation in response to the irrelevant antigen OVA was similar
to background in both groups.
Similarly, production of IL-10 and IL-2 was increased in
response to E-selectin in the culture supernatant of cells from E-
selectin treated mice (Figure 4B, C). The TGF-b levels in the
culture supernatant were similar for both treatment groups
(Figure 4D). This specificity to E-selectin is similar to data
obtained in wild-type C57BL/6 mice with and without experi-
mental autoimmune encephalomyelitis (EAE; Jacqueline A.
Quandt, unpublished data, 2010). The levels of IL-4, IL-17, IFNc
and TNFa in cell culture supernatant remained below low pg/ml
detection limits in both treatment regimens with or without the
presence of E-selectin in culture (data not shown).
Effects of E-selectin tolerization on mRNA expression in
the aorta
Microarray analysis of mRNA was carried out in the pre-
tolerization regimen B exhibiting significant alterations in lipid
deposition and serum cholesterol as markers of atherosclerosis.
119/13,342 transcripts have an uncorrected P-value , 0.05 and
an absolute fold-change difference $1.25 between the 2 treatment
groups. Those gene fragments mapped to 9 known genes which
were all down-regulated in the group receiving E-selectin (Table 2).
CCL21 is associated with inflammatory and vascular processes
and its association to atherosclerosis has been previously defined
[30]. Although CCL21 had the highest P-value (0.049) of genes
identified as significant by microarray analysis, we investigated and
confirmed by real-time PCR that CCL21 mRNA expression is
indeed significantly down-regulated in the E-selectin group
compared to PBS group (–1.75 fold, P=0.02). Additional analysis
of other genes involved in inflammation, lipid metabolism,
chromatin modification and transcriptional regulation identified
by microarray [31,32] was beyond the scope of this study.
Serum soluble E-selectin, ICAM-1, VCAM-1, and TGF-b
As a gauge of endothelial activation, we monitored serum soluble
E-selectin,ICAM-1and VCAM-1, butfound no differencebetween
the two treatment groups in either regimen (Table 1). As TGF-b is
implicated in the effector function of some Treg subsets [9], we
measured serum TGF-b levels in mice on regimen B. E-selectin
tolerization decreased serum active TGF-ß (0.6160.05 ng/ml in
PBS group vs. 0.4960.03 ng/ml in E-selectin group, P=0.04,
N=23 per group). Serum total TGF-b was similar among the two
groups (91.3864.07 ng/ml in PBS group vs. 85.5564.62 ng/ml in
E-selectingroup, P=0.35,N=23 per group). Serum IL-10,CCL21
and IFNc were below the kit detection limits.
Serum E-selectin specific antibodies
In both of the A and B regimens, serum human E-selectin-
specific IgG1 and total IgG were detected in E-selectin tolerized
mice (Figure 5A), whereas IgG2a levels were similarly low in both
groups. The elevated serum IgG1 was proportional to elevated
serum total IgG. Serum mouse E-selectin-specific IgG1 and total
IgG were increased in E-selectin tolerized mice and the elevated
serum IgG1 was proportional to elevated serum total IgG
(Figure 5B), demonstrating cross-reactivity of human E-selectin
specific antibodies to mouse E-selectin. Serum E-selectin- specific
IgM was analyzed in regimen A; available serum was insufficient
for this analysis in regimen B. E-selectin specific IgM did not differ
between treatment groups, which is consistent with our studies in
C57BL/6 mice with and without EAE (data not shown).
Background antibody binding was negligible when OVA was
used to coat the ELISA plates. The absorbance of serum from PBS
or E-selectin treated mice was as low as the no serum control;
whereas the serum levels of OVA-specific IgG and IgG1 were high
in OVA immunized mice (data not shown).
Discussion
Our previous studies in multiple preclinical disease models
(stroke, vascular cognitive impairment, adult neurogenesis after
brain ischemia) and the current study in atherosclerosis, have all
shown that intranasal delivery of E-selectin leads to salutary
mechanisms that are safe and effective. The suppression of
atherogenesis after E-selectin tolerization is a new and highly
desirable mechanism of action for this innovation in stroke
prevention since 80% of ischemic strokes are caused by arterial
occlusion secondary to atherosclerosis [33].
As we explored E-selectin tolerization in a mouse model of
atherosclerosis, we tested two regimens of E-selectin administra-
tion either preceding (regimen B) or delivered simultaneously
(regimen A) with a high-fat diet. The reduction of serum total
cholesterol and lipid lesion on the ascending aorta and arch was
statistically significant in regimen B, but not in regimen A.
Regimen A may not have had sufficient power to detect the
difference, yet a second marker of E-selectin efficacy, total
cholesterol, also showed very little variation in this regimen and
instead suggests a less effective regimen. Notably, lipid lesions on
the aorta were quantitated 2 weeks after E-selectin tolerization in
regimen A and 7 weeks after E-selectin tolerization in regimen B,
suggesting that E-selectin tolerization may need more time to have
an effect, particularly if atherosclerosis secondary to diet was
already well underway. Furthermore, the mice were older in
regimen B and displayed more atherosclerosis, suggesting the
effect of E-selectin tolerization may be more robust or at a
minimum easier to detect at a more advanced stage of disease.
Decreased serum total cholesterol in E-selectin tolerized mice is
of interest and further study is needed to characterize the
mechanisms responsible for this reduction. It is however notable,
that immune cells have been shown to directly influence plasma
total cholesterol level [34] and that increased IL-10 expression
reduces serum total cholesterol in ApoE2/2 mice [35].
In the present study, intranasal delivery of E-selectin gave rise to
E-selectin specific responses measureable by a reduction in Th1
mediated hypersensitivity, E-selectin specific cytokine production
as well as E-selectin-specific IgG/IgG1 antibodies consistent with
an immunosuppressive isotype. Intranasal delivery of E-selectin
reduced DTH, an antigen-specific Th1 response, in C57BL/6
mice with efficacy similar to that previously observed in rats
[24,26]. No significant reductions in swelling/responses were
observed in animals receiving the irrelevant antigen OVA, further
emphasizing the importance of specificity for E-selectin. Cytokine
and antibody responses were detectable in both regimens A and B,
yet slightly greater proliferation and cytokine responses in regimen
B may reflect an association between the robustness of responses
and the greater time for responses to develop after tolerization has
been completed (2 weeks in regimen A vs. 7 weeks in regimen B).
Mucosal delivery of antigen can induce antigen specific regulatory
or tolerogenic cells [16,36,37,38], thus intranasal delivery of E-
selectin in atherosclerosis plausibly involves the generation of E-
selectin specific regulatory cells. We observed increased IL-10 and
IL-2 production upon E-selectin stimulation in splenocytes from E-
selectin treated mice. IL-10 was the primary effector cytokine
produced in tolerized animals in response to E-selectin, and was
also increased in splenocyte cultures of E-selectin tolerized animals
E-Selectin Tolerization in ApoE2/2 Mice
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20620E-Selectin Tolerization in ApoE2/2 Mice
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20620exhibiting less ischemic brain injury [24]. IL-10 producing cells
possess a regulatory capacity and studies have shown that IL-10
itself is anti-atherogenic [39,40,41]. While IL-2 is considered the
prototypical autocrine cytokine and T cell mitogen [42], IL-2 is
vital for the development, expansion, and function of Tregs
[8,43,44].
E-selectin-specific IgG1 and total IgG were increased in mice
receiving E-selectin with a relative paucity of IgG2a antibodies.
However, the lesion sizes were not correlated with antibody titers
(data not shown). The predominance of IgG1 over IgG2a
antibodies is consistent with the immunomodulatory rather than
proinflammatory nature of the response to E-selectin observed in
lymphoid tissues, as it was reported that Th1 associated cytokines
support the production of IgG2a antibodies while Th2 associated
cytokines support the secretion of IgG1 antibodies in mice [45].
Quantitatively similar responses to human or mouse E-selectin by
ELISA demonstrated the high degree of cross reactivity of
antibodies generated in E-selectin tolerized animals and empha-
sizes the potential for responses against and efficacy in animals
generating only the mouse form of E-selectin. The distinction
between binding and neutralizing antibodies specific for E-selectin
was beyond the scope of our study; however we cannot rule out
any additional effects which may be antibody-mediated.
Our study demonstrated that E-selectin tolerization reduced
gene expression of the chemoattractant cytokine CCL21, a key
modulator of inflammation [46,47] along with other lipid and
inflammation-related molecules which were beyond the scope of
this study. As well as being up-regulated in clinical and
experimental atherosclerosis [48], CCL21 is also involved in
neuroinflammation [49,50,51], suggesting how reductions in this
chemokine secondary to intranasal E-selectin may also be
beneficial in stroke.
Previous studies involving intranasal administration of E-selectin
have implicated Tregs as contributors to reductions in vascular
activation or associated immune responses. CD3 and Foxp3+ cells
were negligible by IHC analysis, and mRNA expression of IL-10
or Foxp3 in the aorta was not different between treatment groups.
This may be attributable to: 1) the timing of examination not
being consistent with the presence of regulatory cells or 2) the
location of antigen presentation and immunoregulation occurring
outside the aorta. Notably, CCR7 – the ligand of CCL21 – is
expressed at high levels on the majority of Foxp3+ Tregs [52], and
reduced CCL21 expression in mice receiving E-selectin would
foreseeably limit rather than enhance their recruitment at the site
of disease.
Reduced serum active TGF-b in E-selectin tolerized mice may
result from increased matrix deposition[53] or reduced production
of active TGF-b. TGF-b has pro-atherogenic or anti-atherogenic
effects in different stages of atherosclerosis [54,55,56]. As serum
active TGF-b is correlated with coronary artery disease [57,58],
reduced serum active TGF-b in E-selectin tolerized mice may be
consistent with benefit; however, an absolute or conclusive role for
TGF-b in repair or pathogenesis remains unclear.
One may postulate deleterious effects associated with E-selectin
administration, such as autoimmunity, interference with inflam-
matory cell trafficking and infiltration during tissue repair or
infection resulting from immunosuppression. Upon challenge with
influenza virus, mice receiving E-selectin showed similar resistance
and survival to PBS-tolerized mice (John M. Hallenbeck,
unpublished data, 2009). Because soluble E-selectin is critical in
recruiting endothelial progenitor cells for repair processes [59], it is
notable that the level of serum E-selectin is comparable between
the treatment groups in our experiments limiting the potential for
reduced progenitor recruitment. The effector profile of E-selectin
specific cells as well as the antibody isotype is immunomodulatory
rather than typical of proinflammatory or autoimmune-associated
profiles. Moreover, IL-10 promotes regenerative healing in injured
skin [60], recovery from spinal cord injury [61], and myocardial
infarct recovery [62], thus its production in response to E-selectin
likely contributes to protection rather than pathogenesis. The
pattern of altered gene expression consistent with reduced
inflammation and E-selectin tolerization found to augment brain
Table 2. Intranasal administration of E-selectin down-regulated mRNA expression of 9 genes in the aorta of ApoE2/2 mice.
Gene Symbol Fold change Uncorrected P-value Gene Description
FUT11 22.538 0.015 Fucosyltransferase 11
DUB2A 22.399 0.003 Deubiquitinating enzyme 2a
CCL21 21.554 0.049 Chemokine (C-C motif) ligand 21
MACROD2 21.513 0.018 MACRO domain containing 2
HIST1H2BG 21.309 0.017 Histone cluster 1, H2BG
CFB 21.286 0.021 Complement factor B
SFRP4 21.275 0.037 Secreted frizzled-related protein 4
C4A 21.273 0.043 Complement component 4A
APOC1 21.255 0.021 Apolipoprotein C-I
Animals receiving PBS or E-selectin (regimen B; N=3 and 4 respectively) were analyzed 10 weeks after a high-fat diet.
doi:10.1371/journal.pone.0020620.t002
Figure 4. Intranasal delivery of E-selectin induces E-selectin specific regulatory cells. After 7 weeks on a high-fat diet, splenocytes were
collected and cultured in X-vivo 15 alone or with 20 mg/ml E-selectin or 20 mg/ml OVA. Supernatant was collected at 72 h. Bars represent the mean of
5 animals per treatment group, error bars represent the SEM. (A) Intranasal delivery of E-selectin induces E-selectin specific immune cells. Proliferation
measured by thymidine incorporation was only increased in splenocytes from animals that received intranasal delivery of E-selectin and only
specifically in response to E-selectin (not the irrelevant antigen OVA). (B) Splenocytes from E-selectin tolerized mice produced more IL-10 in culture
upon E-selectin stimulation. (C) Splenocytes from E-selectin tolerized mice produced more IL-2 in culture upon E-selectin stimulation. (D) Splenocytes
from both treatment groups produced a similar amount of TGF-b with or without E-selectin or OVA stimulation.
doi:10.1371/journal.pone.0020620.g004
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ischemic adult neurogenesis [25] further suggest protective roles
for E-selectin.
Additional studies are needed to investigate the long-term effect
of E-selectin tolerization and to fully elucidate the role of E-selectin
tolerization in atherosclerosis. The suppression of atherosclerosis,
an important forerunner of acute ischemic cerebrovascular
syndromes as well as diseases affecting other organs and vascular
beds, provides further support for E-selectin tolerization as a
promising strategy for prevention of stroke and other vascular
diseases.
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